ClinicalTrials.gg

Program

ROS1/NTRK Inhibitor ANS03

Its studies are led by Avistone Biotechnology.

Furthest: phase 1, since Nov 29, 20241 company-led study, 1 open or runningNext primary completion: Dec 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Avistone Biotechnology11 open or runningphase 1since Nov 29, 2024Nov 29, 2024Dec 30, 2027phase 1 · NCT06716138

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 29, 2024First study: phase 1 study in Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK AlterationFirst studyNCT06716138 · 96 planned · United States, China

Ahead

  1. Dec 30, 2027Primary completion: phase 1 study in Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK AlterationNCT06716138

TargetBeta

ROS1 →read by rule
“An orally bioavailable type II inhibitor of the receptor tyrosine kinase c-ros oncogene 1 (ROS1) and the neurotrophic tyrosine receptor kinases (NTRKs), ”NCIt, by rule

Other programs on ROS1

ProgramCompanyFurthest phaseStudies
CrizotinibrulePfizerphase 431
taletrectinibruleNuvation Biophase 311
repotrectinibruleBristol-Myers Squibbphase 39
Fudotinibruleguangzhou-joyo-pharma-co-ltdphase 33
Cross-over to JYP0322ruleguangzhou-joyo-pharma-co-ltdphase 31
Radiosensitizer VS-101rulevspharmtech-co-ltdphase 22
SIM0518ruleSimcere Pharmaceutical Groupphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06716138Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration · United States, China1RecruitingDec 30, 202796

How it is read

Names in the registry

  • “ANS03”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.